Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. It has the benefit to in-situ characterize and measure biomarkers, while determining their specific cellular and tissue localizations. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.

Other products and services from Trans-hit Biomarkers

Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain.
At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product.

Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy.
Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.

In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage.
Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests.